Efficacy of in-class IL-23 inhibitor switching: Risankizumab following Guselkumab failure in moderate-to-severe psoriasis treatment.

Efficacy of in-class IL-23 inhibitor switching: Risankizumab following Guselkumab failure in moderate-to-severe psoriasis treatment. Br J Dermatol. 2020 Sep 30;: Authors: Reddy R, Pannu S, Fiumara K, Kahn J, Rosmarin D Abstract The development of drugs that target the Th17 axis has had a profound effect on the treatment and management of psoriasis. IL-23 inhibitors in particular, including guselkumab and risankizumab have been shown to be highly effective and have a favorable safety profile.1 Though recent studies have shown that in-class biologic switching can be effective in the treatment of psoriasis, no investigation has assessed the efficacy of an in-class IL-23 inhibitor switch.2,3. PMID: 32998185 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research